drugset / Trial / NCT00629642

Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis

NCT00629642

Phase 4 Completed 249 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A clinical study to evaluate the efficacy and safety of solifenacin in patients with bladder symptoms due to spinal cord injury or multiple sclerosis

Timeline

Start
2008-03-14
Primary completion
2011-01-28
Completion
2011-01-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxybutynin Small molecule 5 mg Oral
Subject Solifenacin Small molecule 5 mg Oral
Subject Solifenacin Small molecule 10 mg Oral